Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3746623 | 1.00 | LTA4H (0.50) | LTA4HALDH1A1SMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL743297 | 0.92 | LTA4H (0.58) | LTA4HALDH1A1EPHX2MEN1KMT2A | |
| SCHEMBL744389 | 0.90 | LTA4H (0.59) | LTA4HALDH1A1MAPK1EPHX2MEN1 | |
| SCHEMBL745327 | 0.89 | LTA4H (0.56) | LTA4HALDH1A1MAPK1EPHX2MEN1 | |
| SCHEMBL15252177 | 0.89 | LTA4H (0.49) | LTA4HEPHX2KCNH2 | |
| SCHEMBL13051179 | 0.86 | LTA4H (0.54) | LTA4HALDH1A1TSHREPHX2KCNH2 | |
| SCHEMBL15252279 | 0.85 | LTA4H (0.54) | LTA4HEPHX2KCNH2 | |
| SCHEMBL15252064 | 0.85 | LTA4H (0.53) | LTA4HEPHX2KCNH2 | |
| SCHEMBL15252176 | 0.84 | LTA4H (0.50) | LTA4HEPHX2KCNH2 | |
| SCHEMBL743021 | 0.84 | LTA4H (0.60) | LTA4HEPHX2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | claimed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | LTA4H 1/4885ALDH1A1 1950/4885SMN1; SMN2 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.